Patent ID: 8192721

Claim:
A composition comprising a gadolinium-based contrast agent and a derivatized cyclodextrin wherein the molar ratio of said agent to said cyclodextrin is from about 2:1 to 50:1; wherein the gadolinium-based contrast agent is selected from the group consisting of gadodiamide, gadoversetamide, gadopentetate dimeglumine, gadobenate dimeglumine, gadoteridol, gadoxetic acid disodium salt, gadofosveset trisodium, gadobutrol, and gadoterate meglumine; and wherein said derivatized cyclodextrin is of the formula: cyclodextrin-[(O—R—Y) − (Me) + ] n where R is selected from the group consisting of straight-chained or branched C 1-10 alkyl, alkenyl or alkynyl; C 3-8 cycloalkyl and C 3-8 aryl, each ring optionally containing a heteroatom selected from S, N and O; and optionally substituted with halo or hydroxyl; Y is an anionic group selected from the group consisting of COO, SO 4 , SO 3 , PO 3 H and PO 4 ; Me is a pharmaceutically acceptable cation; and n is a number greater than or equal to 1; and wherein said derivatized cyclodextrin is present in an amount effective for inhibiting the toxic effect of said agent.